Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.

Painter, George R; Natchus, Michael G; Cohen, Oren; Holman, Wendy; Painter, Wendy P

Painter, George R; Natchus, Michael G; Cohen, Oren; Holman, Wendy; Painter, Wendy P.

Afiliación

Painter GR; Emory Institute for Drug Development (EIDD), Emory University, Atlanta, GA, USA; Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA, USA; Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: George.r.painter@emory.edu.
Natchus MG; Emory Institute for Drug Development (EIDD), Emory University, Atlanta, GA, USA.
Cohen O; Covance Clinical Research Unit Ltd., Springfield House, Hyde Street, Leeds LS2 9LH, UK.
Holman W; Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, USA.
Painter WP; Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, USA.

Curr Opin Virol ; 50: 17-22, 2021 10.

Article en En | MEDLINE | ID: mdl-34271264

Asunto(s)

Antivirales/uso terapéutico; Tratamiento Farmacológico de COVID-19; Citidina/análogos & derivados; Hidroxilaminas/uso terapéutico; SARS-CoV-2/efectos de los fármacos; Administración Oral; Citidina/uso terapéutico; Humanos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 3_ND Problema de salud: 3_chikungunya Asunto principal: Antivirales / Citidina / SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 / Hidroxilaminas Límite: Humans Idioma: En Revista: Curr Opin Virol Año: 2021 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google